Danish drugmaker Novo Nordisk will reduce the U.S. list prices of some of its most widely used insulin products by as much as 75%, the company announced Tuesday.
A pharmacist in York reacts to the news that Eli Lilly will cap insulin prices for customers with insurance at $35 and saving some people hundreds of dollars.